146 related articles for article (PubMed ID: 34226971)
1. Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy.
Kawashima I; Oishi N; Kasai K; Inoue T; Hosokawa E; Nakadate A; Matsuura M; Kumagai T; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kondo T; Kirito K
Virchows Arch; 2022 May; 480(5):1101-1105. PubMed ID: 34226971
[TBL] [Abstract][Full Text] [Related]
2. Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma.
Kumar J; Al-Kawaaz M; Martin BA; Hegazi MM; Tan B; Gratzinger D
Am J Clin Pathol; 2022 Oct; 158(4):449-455. PubMed ID: 35964234
[TBL] [Abstract][Full Text] [Related]
3. Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.
Miao Y; Wang R; Fan L; Qiu H; Wu Y; Chen Y; Xu W; Li J
Int J Clin Exp Pathol; 2015; 8(6):7494-8. PubMed ID: 26261659
[TBL] [Abstract][Full Text] [Related]
4. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.
Nadeu F; Martin-Garcia D; Clot G; Díaz-Navarro A; Duran-Ferrer M; Navarro A; Vilarrasa-Blasi R; Kulis M; Royo R; Gutiérrez-Abril J; Valdés-Mas R; López C; Chapaprieta V; Puiggros M; Castellano G; Costa D; Aymerich M; Jares P; Espinet B; Muntañola A; Ribera-Cortada I; Siebert R; Colomer D; Torrents D; Gine E; López-Guillermo A; Küppers R; Martin-Subero JI; Puente XS; Beà S; Campo E
Blood; 2020 Sep; 136(12):1419-1432. PubMed ID: 32584970
[TBL] [Abstract][Full Text] [Related]
5. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
[TBL] [Abstract][Full Text] [Related]
6. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
[TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
[TBL] [Abstract][Full Text] [Related]
9. Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma.
Schneider S; Crescenzi B; Schneider M; Ascani S; Hartmann S; Hansmann ML; Falini B; Mecucci C; Tiacci E; Küppers R
Int J Cancer; 2014 Feb; 134(4):832-43. PubMed ID: 23929122
[TBL] [Abstract][Full Text] [Related]
10. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
11. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
13. Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy.
Karolová J; Kazantsev D; Svatoň M; Tušková L; Forsterová K; Maláriková D; Benešová K; Heizer T; Dolníková A; Klánová M; Winkovska L; Svobodová K; Hojný J; Krkavcová E; Froňková E; Zemanová Z; Trněný M; Klener P
Am J Hematol; 2023 Oct; 98(10):1627-1636. PubMed ID: 37605345
[TBL] [Abstract][Full Text] [Related]
14. Novel agents for mantle cell lymphoma: molecular rational and clinical data.
Sarkozy C; Ribrag V
Expert Opin Investig Drugs; 2020 Jun; 29(6):555-566. PubMed ID: 32321318
[TBL] [Abstract][Full Text] [Related]
15. An Uncommon Case of Double-Hit Mantle Cell Lymphoma That Demonstrates a Transformation Process.
Zhou J; Hu L; Zuo M; Zhou Y; Li G; Zhang X
Am J Clin Pathol; 2020 Jan; 153(1):49-57. PubMed ID: 31433838
[TBL] [Abstract][Full Text] [Related]
16. [Composite lymphoma cosisting of mantle cell lymphoma and follicular lymphoma].
Matsuoka A; Tsushima T; Tanibuchi M; Katsuki N; Kushida Y; Takata K; Taoka T
Rinsho Ketsueki; 2013 Nov; 54(11):2056-61. PubMed ID: 24305539
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
[TBL] [Abstract][Full Text] [Related]
18. NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications.
Deshotels L; Safa FM; Saba NS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373427
[TBL] [Abstract][Full Text] [Related]
19.
Martín-Garcia D; Navarro A; Valdés-Mas R; Clot G; Gutiérrez-Abril J; Prieto M; Ribera-Cortada I; Woroniecka R; Rymkiewicz G; Bens S; de Leval L; Rosenwald A; Ferry JA; Hsi ED; Fu K; Delabie J; Weisenburger D; de Jong D; Climent F; O'Connor SJ; Swerdlow SH; Torrents D; Beltran S; Espinet B; González-Farré B; Veloza L; Costa D; Matutes E; Siebert R; Ott G; Quintanilla-Martinez L; Jaffe ES; López-Otín C; Salaverria I; Puente XS; Campo E; Beà S
Blood; 2019 Feb; 133(9):940-951. PubMed ID: 30538135
[TBL] [Abstract][Full Text] [Related]
20. Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
Assis-Mendonça GR; Fattori A; Rocha RM; Lourenço GJ; Delamain MT; Nonogaki S; de Lima VCC; Colleoni GWB; de Souza CA; Soares FA; Lima CSP; Vassallo J
BMC Cancer; 2021 Mar; 21(1):209. PubMed ID: 33648463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
